DS-1 (drug)
 | |
| Identifiers | |
|---|---|
| |
| CAS Number | |
| PubChem CID | |
| IUPHAR/BPS | |
| ChemSpider | |
| CompTox Dashboard (EPA) | |
| ECHA InfoCard | 100.209.966 |
| Chemical and physical data | |
| Formula | C18H10Br2ClN3OS |
| Molar mass | 511.62 g·mol−1 |
| 3D model (JSmol) | |
| |
| (verify) | |
DS-1 is a drug from the imidazopyridine family, which is the first drug developed that acts as a GABAA receptor positive allosteric modulator (PAM) selective for the α4β3δ subtype, which is not targeted by other GABAA receptor PAMs such as the benzodiazepines or other nonbenzodiazepine drugs. Novel selective drugs such as DS-1 are useful in the study of this receptor subtype.[1][2][3]
See also
[edit]References
[edit]- ^ Wafford KA, van Niel MB, Ma QP, Horridge E, Herd MB, Peden DR, et al. (January 2009). "Novel compounds selectively enhance delta subunit containing GABA A receptors and increase tonic currents in thalamus". Neuropharmacology. 56 (1): 182–189. doi:10.1016/j.neuropharm.2008.08.004. PMID 18762200. S2CID 207224202.
- ^ Yakoub K, Jung S, Sattler C, Damerow H, Weber J, Kretzschmann A, et al. (March 2018). "Structure-Function Evaluation of Imidazopyridine Derivatives Selective for δ-Subunit-Containing γ-Aminobutyric Acid Type A (GABAA) Receptors". Journal of Medicinal Chemistry. 61 (5): 1951–1968. doi:10.1021/acs.jmedchem.7b01484. PMID 29451785.
- ^ Solomon VR, Tallapragada VJ, Chebib M, Johnston GA, Hanrahan JR (June 2019). "GABA allosteric modulators: An overview of recent developments in non-benzodiazepine modulators". European Journal of Medicinal Chemistry. 171: 434–461. doi:10.1016/j.ejmech.2019.03.043. PMID 30928713. S2CID 89619321.
 | This sedative-related article is a stub. You can help Wikipedia by expanding it. |